Emulsión lipídica intravenosa para revertir la toxicidad farmacológica aguda en pacientes pediátricos

Translated title of the contribution: Intravenous lipid emulsion to reverse acute drug toxicity in pediatric patients

Joseph D. Presley, Peter Chyka

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Objective: To identify and summarize published cases in which intravenous lipid emulsion was used to treat pediatric patients with acute drug toxicities. Data Sources: PubMed, SCOPUS, and EMBASE were searched up to December 2012 for relevant publications using the terms fat emulsion, lipid emulsion, Intralipid, Liposyn, Medialipide, Medialipid, lipid rescue, ILE, IVLE, IFE, IVFE, or lipid and intoxication, overdose, poisoning, toxicity, resuscitation, antidote, and rescue that were limited to reports in humans aged 18 years or younger. Study Selection and Data Extraction: A publication was included if an intravenous lipid emulsion was used to treat acute-onset drug toxicity as reported in prospective or retrospective observational studies, case reports, and abstracts for patients aged 18 years or younger. Data Synthesis: Fourteen case reports were identified in which intravenous lipid emulsion was used to treat toxicities due to local anesthetics and other medications (amitriptyline, diltiazem, bupropion, dosulepin, lamotrigine, quetiapine, and verapamil). Thirteen cases demonstrated a beneficial response in reversing systemic toxicity; 1 of these patients developed hypertriglyceridemia and pancreatitis. The dosage regimens used in this series were dissimilar. Conclusions: There is an increasing interest in use of intravenous lipid emulsions to treat life-threatening toxicity from several lipophilic drugs in adults and children. Although most of the literature describes adult cases, intravenous lipid emulsion has been used in neonates and adolescents, with generally positive outcomes. Given the life-threatening, sometimes near-death situations in which an intravenous lipid emulsion is typically used after conventional resuscitation is unsuccessful and the dramatic positive response to this therapy in most published cases, its use likely will continue. Continued reporting of pediatric cases will guide the optimal use and safety profile of intravenous lipid emulsion for the emergent reversal of drug toxicity.

Original languageSpanish
Pages (from-to)735-743
Number of pages9
JournalAnnals of Pharmacotherapy
Volume47
Issue number5
DOIs
StatePublished - May 1 2013

Fingerprint

Intravenous Fat Emulsions
Drug-Related Side Effects and Adverse Reactions
Pediatrics
Emulsions
Lipids
Resuscitation
Publications
Dothiepin
Bupropion
Antidotes
Amitriptyline
Diltiazem
Hypertriglyceridemia
Information Storage and Retrieval
Verapamil
Local Anesthetics
PubMed
Pancreatitis
Poisoning
Observational Studies

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this

Emulsión lipídica intravenosa para revertir la toxicidad farmacológica aguda en pacientes pediátricos. / Presley, Joseph D.; Chyka, Peter.

In: Annals of Pharmacotherapy, Vol. 47, No. 5, 01.05.2013, p. 735-743.

Research output: Contribution to journalArticle

@article{04b2f117f4b94aefa1f5175fd4904016,
title = "Emulsi{\'o}n lip{\'i}dica intravenosa para revertir la toxicidad farmacol{\'o}gica aguda en pacientes pedi{\'a}tricos",
abstract = "Objective: To identify and summarize published cases in which intravenous lipid emulsion was used to treat pediatric patients with acute drug toxicities. Data Sources: PubMed, SCOPUS, and EMBASE were searched up to December 2012 for relevant publications using the terms fat emulsion, lipid emulsion, Intralipid, Liposyn, Medialipide, Medialipid, lipid rescue, ILE, IVLE, IFE, IVFE, or lipid and intoxication, overdose, poisoning, toxicity, resuscitation, antidote, and rescue that were limited to reports in humans aged 18 years or younger. Study Selection and Data Extraction: A publication was included if an intravenous lipid emulsion was used to treat acute-onset drug toxicity as reported in prospective or retrospective observational studies, case reports, and abstracts for patients aged 18 years or younger. Data Synthesis: Fourteen case reports were identified in which intravenous lipid emulsion was used to treat toxicities due to local anesthetics and other medications (amitriptyline, diltiazem, bupropion, dosulepin, lamotrigine, quetiapine, and verapamil). Thirteen cases demonstrated a beneficial response in reversing systemic toxicity; 1 of these patients developed hypertriglyceridemia and pancreatitis. The dosage regimens used in this series were dissimilar. Conclusions: There is an increasing interest in use of intravenous lipid emulsions to treat life-threatening toxicity from several lipophilic drugs in adults and children. Although most of the literature describes adult cases, intravenous lipid emulsion has been used in neonates and adolescents, with generally positive outcomes. Given the life-threatening, sometimes near-death situations in which an intravenous lipid emulsion is typically used after conventional resuscitation is unsuccessful and the dramatic positive response to this therapy in most published cases, its use likely will continue. Continued reporting of pediatric cases will guide the optimal use and safety profile of intravenous lipid emulsion for the emergent reversal of drug toxicity.",
author = "Presley, {Joseph D.} and Peter Chyka",
year = "2013",
month = "5",
day = "1",
doi = "10.1345/aph.1R666",
language = "Spanish",
volume = "47",
pages = "735--743",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "5",

}

TY - JOUR

T1 - Emulsión lipídica intravenosa para revertir la toxicidad farmacológica aguda en pacientes pediátricos

AU - Presley, Joseph D.

AU - Chyka, Peter

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Objective: To identify and summarize published cases in which intravenous lipid emulsion was used to treat pediatric patients with acute drug toxicities. Data Sources: PubMed, SCOPUS, and EMBASE were searched up to December 2012 for relevant publications using the terms fat emulsion, lipid emulsion, Intralipid, Liposyn, Medialipide, Medialipid, lipid rescue, ILE, IVLE, IFE, IVFE, or lipid and intoxication, overdose, poisoning, toxicity, resuscitation, antidote, and rescue that were limited to reports in humans aged 18 years or younger. Study Selection and Data Extraction: A publication was included if an intravenous lipid emulsion was used to treat acute-onset drug toxicity as reported in prospective or retrospective observational studies, case reports, and abstracts for patients aged 18 years or younger. Data Synthesis: Fourteen case reports were identified in which intravenous lipid emulsion was used to treat toxicities due to local anesthetics and other medications (amitriptyline, diltiazem, bupropion, dosulepin, lamotrigine, quetiapine, and verapamil). Thirteen cases demonstrated a beneficial response in reversing systemic toxicity; 1 of these patients developed hypertriglyceridemia and pancreatitis. The dosage regimens used in this series were dissimilar. Conclusions: There is an increasing interest in use of intravenous lipid emulsions to treat life-threatening toxicity from several lipophilic drugs in adults and children. Although most of the literature describes adult cases, intravenous lipid emulsion has been used in neonates and adolescents, with generally positive outcomes. Given the life-threatening, sometimes near-death situations in which an intravenous lipid emulsion is typically used after conventional resuscitation is unsuccessful and the dramatic positive response to this therapy in most published cases, its use likely will continue. Continued reporting of pediatric cases will guide the optimal use and safety profile of intravenous lipid emulsion for the emergent reversal of drug toxicity.

AB - Objective: To identify and summarize published cases in which intravenous lipid emulsion was used to treat pediatric patients with acute drug toxicities. Data Sources: PubMed, SCOPUS, and EMBASE were searched up to December 2012 for relevant publications using the terms fat emulsion, lipid emulsion, Intralipid, Liposyn, Medialipide, Medialipid, lipid rescue, ILE, IVLE, IFE, IVFE, or lipid and intoxication, overdose, poisoning, toxicity, resuscitation, antidote, and rescue that were limited to reports in humans aged 18 years or younger. Study Selection and Data Extraction: A publication was included if an intravenous lipid emulsion was used to treat acute-onset drug toxicity as reported in prospective or retrospective observational studies, case reports, and abstracts for patients aged 18 years or younger. Data Synthesis: Fourteen case reports were identified in which intravenous lipid emulsion was used to treat toxicities due to local anesthetics and other medications (amitriptyline, diltiazem, bupropion, dosulepin, lamotrigine, quetiapine, and verapamil). Thirteen cases demonstrated a beneficial response in reversing systemic toxicity; 1 of these patients developed hypertriglyceridemia and pancreatitis. The dosage regimens used in this series were dissimilar. Conclusions: There is an increasing interest in use of intravenous lipid emulsions to treat life-threatening toxicity from several lipophilic drugs in adults and children. Although most of the literature describes adult cases, intravenous lipid emulsion has been used in neonates and adolescents, with generally positive outcomes. Given the life-threatening, sometimes near-death situations in which an intravenous lipid emulsion is typically used after conventional resuscitation is unsuccessful and the dramatic positive response to this therapy in most published cases, its use likely will continue. Continued reporting of pediatric cases will guide the optimal use and safety profile of intravenous lipid emulsion for the emergent reversal of drug toxicity.

UR - http://www.scopus.com/inward/record.url?scp=84877093115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877093115&partnerID=8YFLogxK

U2 - 10.1345/aph.1R666

DO - 10.1345/aph.1R666

M3 - Article

C2 - 23613099

AN - SCOPUS:84877093115

VL - 47

SP - 735

EP - 743

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 5

ER -